Announcements

The latest company announcements from Denmark, Sweden, Norway and Finland

Springvest favicon

Springvest Oyj: Arvopaperimarkkinalain 9 luvun 10 § mukainen ilmoitus

Springvest Oyj: Arvopaperimarkkinalain 9 luvun 10 § mukainen ilmoitus

Springvest Oyj on 29.8.2024 vastaanottanut arvopaperimarkkinalain 9. luvun 5. pykälän mukaisen liputusilmoituksen, jonka mukaan Markku Jussilan suora omistusosuus yhtiön osakkeista ja äänistä on laskenut alle 5 prosentin liputusrajan 29.8.2024 ja on 4,95 %.

Liputusvelvollisen suora ja välillinen omistus

%-osuus osakkeista ja äänistä

%-osuus osakkeista ja äänistä rahoitusvälineiden kautta

Yhteenlaskettu %-osuus

Kohdeyhtiön osakkeiden ja äänten kokonaismäärä

Osuus liputusrajan saavuttamisen tai rikkoutumisen jälkeen

4,95 %

Edellisessä liputusilmoituksessa ilmoitettu osuus (jos liputettu)

 5,88 %

 

 

 

Tiedot omistus- ja ääniosuudesta liputusrajan saavuttamisen tai rikkoutumisen jälkeen

A: Osakkeet ja äänet

 

Osakkeiden ja äänten lukumäärä

Osakkeiden ja äänten %-osuus

Osakesarja/osakelaji ISIN-koodi

Suora (AML 9:5)

Välillinen (AML 9:6 ja 9:7)

Suora (AML 9:5)

Välillinen (AML 9:6 ja 9:7)

 FI4000369442

239 250

36 909

4,29 %

0,66 %

A YHTEENSÄ

276 159

4,95 %

Tietoja liputusvelvollisesta

Koko määräysvaltaketju (ylintä määräysvaltaa käyttävästä luonnollisesta henkilöstä tai oikeushenkilöstä alkaen), jonka kautta osakkeita, äänioikeuksia tai rahoitusvälineitä hallitaan:

Nimi

%-osuus osakkeista ja äänistä

%-osuus osakkeista ja äänistä rahoitusvälineiden kautta

Osakkeet, äänet ja rahoitusvälineet yhteensä

Markku Jussila

4,29

0

239 250

Enemmän aikaa consulting oy

0,66

0

36 909

   

Lisätietoja 

Springvest Oyj, toimitusjohtaja Aki Soudunsaari, puhelin 040 822 6322Sähköposti: aki.soudunsaari@springvest.fi

Hyväksytty neuvonantaja, EY Advisory Oy, puhelin 020 728 0190Sähköposti: heikki.saukola@parthenon.ey.com

   

Springvest lyhyesti

Springvest Oyj on First North -markkinapaikalle listattu sijoituspalveluyhtiö, joka yhdistää rahoituskierroksilla suomalaiset maailmaa muuttavat kasvuyhtiöt sekä suurta tuottoa tavoittelevat ja riskinottokykyiset kasvusijoittajat.

Historiansa aikana Springvest on järjestänyt yli 100 onnistunutta rahoituskierrosta ja välittänyt rahoitusta yli 376 miljoonaa euroa. Tulemme jokaisella kierroksella kohdeyhtiön vähemmistöosakkaaksi ja portfolioomme kuuluu tällä hetkellä osakkeita noin 40 yhtiöstä.

www.springvest.fi

Liitteet
  • Lataa tiedote pdf-muodossa.pdf
Finnish

Gofore begins share purchase programme

Gofore Plc Other information disclosed according to the rules of the exchange29 August 2025 11.30 am EET

Gofore begins share purchase programme

Gofore Plc’s Board of Directors has decided to begin a purchase programme of the company’s own shares based on the authorization granted by the Annual General Meeting on 11 April 2025.  Purpose of the purchase programme is to acquire the company’s own shares to be used in obligations related to current and possibly future incentive arrangements the staff of the Gofore Group and share-based rewards paid to key people.

The maximum number of shares to be purchased is 75,000, which corresponds to less than one percent of the company’s shares. However, no more than EUR 1.25 million will be used to acquire the shares. The shares shall be acquired otherwise than in proportion to the holdings of the shareholders in public trading organized by Nasdaq Helsinki Oy at the market price at the time of acquisition or otherwise at market price. The purchase of the company’s own shares shall commence at the earliest on 29 August 2025 and shall end at the latest on 31 October 2025. The purchase of shares will be funded with the company’s distributable unrestricted shareholders’ equity.

Gofore has appointed Allshares Oy as the manager of the share purchase programme. The manager has agreed that Evli Plc makes trading decisions independently. This also applies to the timing of purchases.

Gofore can suspend or terminate the programme before its planned end date. In this case, Gofore issues a related stock exchange release. Before beginning the share purchase programme, Gofore has 4,931 of own shares in its possession. Gofore Plc has a total of 15,742, 834 shares.

The purchases will be carried out in accordance with the so-called safe harbor procedure referred to in the EU Market Abuse Regulation (Regulation No. 596/2014) and the Commission Delegated Regulation (EU) 2016/1052.

 

Contacts
  • Emmi Berlin, IR & PR Lead, +358400903260, emmi.berlin@gofore.com
About Gofore Oyj

Gofore is an international digital transformation consultancy with Finnish roots. We employ nearly 1,500 experts across 18 locations in Finland, Germany, Austria, Spain, and Estonia. With our technology and business expertise, we work for functional, secure and equal services for the digital society and sustainable solutions for the intelligent industry. Our diverse group of professionals share a pioneering ambition to create a more humane and responsible digital world. Our values guide our business: Gofore is a great workplace that thrives on customer success. In 2024, our net sales amounted to EUR 186,2 million. Gofore Plc’s share is listed on the Nasdaq Helsinki Ltd. in Finland. Our vision is to be the most significant digital transformation consultancy in Europe. Discover more about us at gofore.com

English, Finnish

Scanfil share subscriptions with stock options 2022AI

Scanfil plc     Stock exchange release     29 august 2025 at 10.00 a.m. EEST

Scanfil share subscriptions with stock options 2022AI

By 8 August 2025, a total of 68,900 Scanfil plc’s new shares has been subscribed for with the company's stock options 2022AI. For subscriptions made with the stock options 2022AI, the entire subscription price of EUR 421,668.00 will be credited to the reserve for the company’s invested unrestricted equity.

The shares subscribed for with the stock options 2022AI have been registered in the Trade Register on 29 August 2025. The new shares will produce shareholder rights for their shareholders from the date of registration. After the trade registration the total amount of shares is 65,418,893.

The shares will be traded in the main list maintained by Nasdaq Helsinki Ltd together with the old shares as of 1 September 2025.

The share subscription period for stock options 1 May 2025 will end on 30 April 2027.

The terms and conditions of stock options with additional information are available on the company's website at www.scanfil.com/investors.

Scanfil plc

Pasi HiedanpääDirector, Investor Relations and Communicationstel. +358 50 378 2228pasi.hiedanpaa@scanfil.com 

About ScanfilScanfil plc is the largest European stock-listed Electronics Manufacturing Service company (EMS) with EUR 780 million turnover in 2024. It serves global industry leaders in Industrial, Energy & Cleantech as well as the Medtech & Life Science customer segments. Scanfil’s objective is to increase customer value by helping them to become more competitive and to be their global, most preferred supply chain, and long-term manufacturing partner. www.scanfil.com

Attachments
  • Download announcement as PDF.pdf
English, Finnish
Digital Workforce favicon

Digital Workforce Services Plc - Managers' transactions - Lampi

Digital Workforce Services Plc - Managers' transactions - Lampi

____________________________________________

Person subject to the notification requirementName: Lampi, MikkoPosition: Other senior managerIssuer: Digital Workforce Services PlcLEI: 7437008HY6B4UCY0VO75

Notification type: INITIAL NOTIFICATIONReference number: 7437008HY6B4UCY0VO75_20250827193851_36

____________________________________________

Transaction date: 2025-08-28Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTInstrument name: Option Plan 2024Nature of the transaction: ACCEPTANCE OF A STOCK OPTION(X) Linked to stock option programme

Transaction details(1): Volume: 46980 Unit price: 0.00 EUR

Aggregated transactions(1): Volume: 46980 Volume weighted average price: 0.00 EUR

For further information, please contact:

Jussi Vasama, CEO, Digital Workforce Services Plc, Tel. +358 50 380 9893 

Certified advisor 

Aktia Alexander Corporate Finance Oy, Tel. +358 50 520 4098

About Digital Workforce Services Oyj

About Digital Workforce Services Plc

Digital Workforce Services Plc is a leader in business automation and technology solutions. Its Outsmart platform and services, including Enterprise AI Agent solutions, empower organizations to transform knowledge work, reduce costs, accelerate digitalization, enhance customer experiences, and strengthen their competitive edge. Over 200 large international organizations rely on the company’s services to drive transformation through automation. Digital Workforce has particular expertise in automating healthcare and social care pathways, advancing long-term condition follow-up, improving patient safety, and enhancing the productivity of healthcare professionals. Founded in 2015, Digital Workforce employs over 200 business automation specialists across the US, UK & Ireland, and Northern and Central Europe. The company is listed on the Nasdaq First North Growth Market Finland.

https://digitalworkforce.com 

English, Finnish

Monsenso presents half-year report for 2025

Company announcement no. 06-2025

Copenhagen, 2025.08.29

(This message includes inside information on the outlook for 2025).

Monsenso’s H1 2025 report was approved by the Board of Directors today.

Performance highlights

  • Total revenue was DKK 5,166k (H1 2024: DKK 5,527k).
  • EBITDA was DKK -1,755k (H1 2024: DKK –1,270k).
  • EBIT was DKK -4,066k (H1 2024: DKK –3,484k).
  • Cash from operations was DKK 666k (H1 2024: DKK –3,840k).
  • Cash and cash equivalents were DKK 1,381k (FY 2024: DKK 1,861k).

Business review

We are pleased to report on the results and the development in H1 2025. Our continued commitment to innovation and strategic growth has yielded significant progress across multiple areas.

Commercial Milestones

Implementation revenue grew by 12% in the period, driven by the launch of a digital research platform in Birmingham (UK), which will be used to provide long-term engagement and monitoring of patients with treatment-resistant depression

Our major digital, decentralised patient-centric study on headache/migraine with a global pharmaceutical company was completed with great success. New subscription revenue did not fully offset the completion of this project in the first half of 2025, which is the primary reason for a 16% decline in subscription revenue during this period.

In collaboration with three Spanish partners, we were selected as a vendor for a large project in a public tender in Spain, and the extensive work on this during the next months will contribute to the expected growth of the business for the second half of 2025.

Innovation and Research

Our three major innovation and research projects, Phase V, PERSONAE and MENTBEST are now operational and recruitment of patients is progressing across their total of five studies. However, the projects have been delayed due to difficulties with approvals and patient recruitment, but we now look forward to seeing the results over the next couple of years.

We have added great new functionalities to our digital health platform, including treatment content queue, automated content recommendations and patient screening.

Cash Flow

The payments from customers and credits from suppliers have improved in the period, causing cash from operations to be DKK 0.7m compared to DKK -3.8m in H1 2024.

Unchanged outlook for 2025

For 2025, we expect revenue to be DKK 12-13m, corresponding to growth of 8-16% and an EBIT of DKK -7m to DKK -6m.

Uncertainties and other financial information for 2025 are included in notes 1 and 2.

Management expects to have sufficient liquidity to manage the group's activities for the coming period.

Key figures

 

 

('000 DKK)

H1 2025

H1 2024

Revenue

5,166

5,527

EBITDA

(1,755)

(1,270)

EBIT

(4,066)

(3,484)

Profit (loss) for the year

(3,839)

(3,231)

Cash from operating activities

666

(3,826)

 

 

 

Cash and cash equivalents, end of period

1,381

1,861

Total assets, end of period

14,479

18,490

Equity, end of period

10,354

14,164

 

 

 

Net profit per share (DKK)

(0.06)

(0.07)

End-of-year, number of employees (FTE)

12

12

CEO Thomas Lethenborg and CFO Robert Højer have recorded a video that comments on the half-year report. The link is here: https://www.monsenso.com/investors/.

Disclaimer

This report contains forward-looking statements that are based on the current expectations of the management. All statements regarding the future are subject to inherent risks and uncertainties, and many factors may lead to actual results and developments deviating substantially from what has been expressed or implied in such statements.

Any inquiries regarding this notice should be directed to:

Monsenso

CEOThomas LethenborgTel +45 21 29 88 27E-mail: lethenborg@monsenso.com 

Chairman of the boardPeter Mørch EriksenE-mail: Petermorcheriksen@outlook.com

Certified Adviser

HC Andersen CapitalBredgade 23, 1260 København K

About Monsenso

Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com

Attachments
  • Download announcement as PDF.pdf
  • 250829.1H-2025.financial.report.via.ritzau.pdf
Danish, English

Asuntosalkku Oyj: OMIEN OSAKKEIDEN HANKINTA 28.8.2025

Asuntosalkku Oyj: OMIEN OSAKKEIDEN HANKINTA 28.8.2025

Helsingin Pörssi

Päivämäärä: 28.8.2025Pörssikauppa: OSTOOsakelaji: ASUNTOOsakemäärä: 26 osakettaKeskihinta/osake: 83.0000 EURKokonaishinta: 2 158.00 EUR

Yhtiön hallussa olevat omat osakkeet 28.8.2025tehtyjen kauppojen jälkeen: 11 939 osaketta.

Asuntosalkku Oyj:n puolesta

Lago Kapital OyMaj van Dijk     Jani Koskell

Lisätietoja

Asuntosalkku Oyj

Jaakko SinnemaatoimitusjohtajaPuh. +358 41 528 0329

jaakko.sinnemaa@asuntosalkku.fi

 

Hyväksytty neuvonantajaAktia Alexander Corporate Finance Oy

Puh. +358 50 520 4098

 

Asuntosalkku Oyj

Asuntosalkku on vaihtoehto asuntorahastoille ja suoralle asuntosijoittamiselle. Se on Viron suurin markkinaehtoinen vuokranantaja ja Tallinnan vuokramarkkinoiden edelläkävijä. Asuntosalkku on asuntosijoitusyhtiö, joka keskittyy omistaja-arvon luomiseen. Sijoitukset painottuvat omistusasuntotaloista valikoituihin yksittäisiin asuntoihin, joissa vuokralainen asuu omistusasujien naapurina. Pääpaino on hyvien sijaintien pienissä asunnoissa Suomen pääkaupunkiseudulla ja sen kehyskunnissa sekä Tallinnan keskusta-alueilla.

31.3.2025 Asuntosalkku omisti Suomessa 1 413 valmista asuntoa, joiden yhteenlaskettu käypä arvo velattomana oli 160,1 miljoonaa euroa, sekä Tallinnassa 676 valmista asuntoa, joiden yhteenlaskettu käypä arvo oli 104,2 miljoonaa euroa. Asuntosalkun taloudellinen vuokrausaste 30.6.2025 oli 97,3 prosenttia.

Asuntosalkun perustajat ovat Jaakko Sinnemaa ja Timo Metsola. He ovat yhtiöidensä kautta myös Asuntosalkun keskeisiä omistajia.

 

www.asuntosalkku.fi

Liitteet
  • Lataa tiedote pdf-muodossa.pdf
  • DEV-ASUNTO_SBB_trades_20250828.xlsx
Finnish

Thor Medical ASA interim results for 1H 2025 – strong operational and commercial progress

Oslo, 29 August 2025: Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, today announced interim results for the first half year 2025. The company is still in an early commercial phase, with the results and operating cash flow reflecting the start of construction of AlphaOne, the company’s first commercial plant for production of high-quality radioisotopes for use in novel cancer treatments.

The development of new targeted alpha therapies (TAT) continued to attract a lot of interest in the cancer community and opens large market opportunities for us Thor Medical as a leading supplier of thorium-228 to power new and effective cancer treatments.    

Achievements in the first half of 2025 include:

  • Final investment decision for AlphaOne taken; the Company's first commercial scale manufacturing facility
  • Strategic sourcing agreement for feedstock of thorium-232 entered with European chemical group
  • First batch of ultra-high purity Pb-212 shipped for preclinical use at big pharma customer
  • Strategic sales agreement for thorium-228 signed with an undisclosed global leader in target alpha therapy
  • Funding for AlphaOne completed with an equity raise for increased capacity of approximately NOK 85 million in June; raised total equity of NOK 300 million and NOK 90 million loan commitment from Innovation Norway

After the end of the reporting period, the company has further broadened its customer portfolio with the signing of strategic sales agreement with new client Oncoinvent, as well as an expanded agreement with AdvanCell.

Financially, Thor Medical reported revenue of NOK 0.1 million, reflecting delivery of its first batch of P2-212. The EBITDA-loss for the period was NOK 23.1 million, with payroll and related expenses of NOK 13.1 million and other expenses of NOK 10.0 million net of grants. Net cash flow including financing was NOK 101 million, leaving the company with available cash of NOK 224.3 million at the end of June 2025.   

“The first half of 2025 has been a defining period for Thor Medical. Most notably, we made the decision to build AlphaOne, our first commercial-scale production plant, marking a major step forward in our strategy to industrialize the supply of thorium-based alpha isotopes for targeted cancer therapies.

We have also strengthened our foundation through several key strategic milestones. During the first half, we secured a long-term raw material supply agreement that ensures stability in our production base, entered into a significant sales agreement with a leading player in targeted alpha therapy, and recorded our first revenues from the sale of Pb-212 to a major pharmaceutical company. Together, these achievements demonstrate our ability to capture the growing addressable market and further establish Thor Medical as the emerging leader in our field.

Our financial position remains strong. We raised substantial capital to fund AlphaOne and, in early summer, decided to increase its planned capacity by 40% in response to strong and growing demand. This reflects both our confidence in the market outlook and our commitment to meet the needs of our partners.

On the ground in Herøya, the construction of AlphaOne is progressing at pace, while our pilot site continues to run efficiently. This facility will be instrumental in shaping the future of radiopharmaceutical supply and will ultimately make a difference to patients around the world.

Beyond Thor Medical, we also see a changing landscape in oncology. Radioligand therapies are increasingly being positioned as a treatment even before chemotherapy, for instance in castration-resistant prostate cancer. This important development clears the way for more effective alpha-emitting therapies to enter the market - with Thor Medical poised to supply the essential isotopes that will power them.

We look forward to the second half of the year with confidence and focus on our key value drivers, building on this strong momentum.” says CEO Jasper Kurth.

A presentation of the results, followed by a Q&A session will be held at Sjøyst Møtesenter, Drammensveien 165, Oslo, today at 08:00 am CET. You can also follow the presentation and Q&A session from our website, or this direct link: Thor Medical Webcast 1H 2025

CONTACTS

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'. To learn more, visit - https://www.thormedical.com.

Attachments
  • Download announcement as PDF.pdf
  • Thor Medical Interim 1H 2025 Report.pdf
  • Thor Medical Interim 1H 2025 Presentation.pdf
English

Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement

Oslo, 29 August 2025: Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and Oncoinvent ASA, a clinical-stage radiopharmaceutical company, have entered into a strategic agreement for Thorium-228 radioisotopes to supply the Phase 3 clinical program for Radspherin®, Oncoinvent’s lead product candidate.

Under the terms of the agreement, Thor Medical will supply Thorium-228 from AlphaOne, the company’s first commercial-scale manufacturing plant currently under construction. Thorium-228 from Thor Medical will serve as the starting material for the manufacture of Radium-224, the key radioisotope in Radspherin®, directly targeting cancers in body cavities. Oncoinvent is currently conducting a randomised Phase 2 trial evaluating Radspherin® for peritoneal carcinomatosis from ovarian cancer.

“We are pleased to have secured additional sources for the supply of Thorium-228 as we advance the planning of our Phase 3 program with Radspherin® for the treatment of peritoneal metastases originating from ovarian cancer. The availability of Thorium-228 within Norway’s expanding radiopharmaceutical ecosystem is of great strategic value and provides the company with significant flexibility,” says Øystein Soug, CEO of Oncoinvent.

“This agreement reflects the growing demand for sustainable and scalable sources of alpha-emitters,” says Jasper C. Kurth, CEO of Thor Medical. “We are seeing the emergence of a vibrant radiopharmaceutical cluster in the greater Oslo region, where world-class research, biotech innovation, and industrial production are coming together. Thor Medical is proud to be part of this ecosystem and to support the development of promising cancer treatments close to home.”

With both companies headquartered in Oslo, this agreement illustrates the strength of Norway’s growing network of radiopharmaceutical companies and targeted alpha therapies. This geographic concentration of scientific, clinical, and industrial capabilities is fostering a highly collaborative environment, positioning Norway as an emerging center for innovation and scalable production in the field of targeted alpha therapies.

CONTACT

Brede Ellingsæter, CFO & COO Thor Medical, +47 472 38 440, brede.ellingseter@thormedical.com,

Tore Kvam, Chief Financial Officer Oncoinvent, kvam@oncoinvent.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

ABOUT ONCOINVENT ASA

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications.  In addition to the finalized phase 1/2a trial in colorectal cancer, one Phase 1 trial and one randomized Phase 2 trial, both in ovarian cancer, are ongoing in the US, UK and Europe. Preliminary clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The experienced Oncoinvent team runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo.

IMPORTANT INFORMATION

This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. The stock exchange announcement was published by Brede Ellingsæter, CFO & COO, Thor Medical ASA, at the time and date stated above in this announcement. This release contains forward -looking information and statements relating to the business, performance, and matters that may impact the results of Thor Medical. Forward-looking statements are statements that are not historical facts and may be identified by words such as "aims," "anticipates," "believes," "estimates," "expects," "foresees," "intends," "plans," "predicts," "projects," "targets," "potential," and similar expressions. Such forward-looking statements are based on current expectations, estimates, and projections, reflect current views concerning future events, and are subject to risks, uncertainties, and assumptions, and may be subject to change without notice. Forward-looking statements are not guarantees of any future performance, and risks, uncertainties, and other important factors could cause the actual business, performance, results, or the industry and markets in which Thor Medical operates to differ materially from the statements expressed or implied in this release by such forward-looking statements. No representation is made that any of these forward-looking statements or forecasts will come to pass or that any forecasted performance, capacities, or results will be achieved, and you are cautioned not to place any undue reliance on any forward-looking statements. This release is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. 

Attachments
  • Download announcement as PDF.pdf
English

Huddlestock - Q2 and H1 2025: Reshaped for future growth in Europe

Huddlestock Fintech AS ("Huddlestock" or the "Company") is pleased to announce that it has carried out a set of strategic moves reshaping the business during the first half of 2025. With reference to the announcement on 14 April 2025, the reshaping includes divestments with effect from 24 April 2025 as divestments with effects subsequent to the reporting period (the “Divestments”). The reshaping of the business includes expansion into continental Europe with its asset light European IaaS Platform, strategic Divestments, CFO appointment, strengthening of its board of directors, and execution on the new strategy for its Consulting business, Visigon.

“The first half of 2025 has truly been a transformative period for Huddlestock. We have succeeded in executing on a series of bold and strategic moves to reshape our business, streamline operations, and position ourselves for a large European market opportunity. With the continued support and confidence among our shareholders, we are currently at the starting point for our new chapter together,” says Leif Arnold Thomas, CEO of Huddlestock.

Year-over-year comparisons may not provide an accurate reflection of the Company’s performance due to the impact of the structural changes related to the Divestments.

The Company reports a total operating income of NOK 31.4 million for the first half of 2025, down from NOK 38.0 million in same period last year. Total operating expenses were NOK 43.9 million, including one-offs related to the Divestments, compared to NOK 47.4 million in the same period last year. The net result for the period was negative NOK 53.9 million carrying effects related to non-realized value change in shares received in the Divestment and losses related to the sale. This compares to negative NOK 35.2 million in the same period last year.

PRO FORMA Q2 2025

On a pro-forma basis, including the full effect of the Divestments and excluding extraordinary transaction costs related to the transaction, Huddlestock reports revenue of NOK 9.0 million and total operating expenses of NOK 13.1 million resulting in a pro-forma EBITDA of negative NOK 4.1 million. Interest costs in the second quarter were NOK 1.9 million, summing up to a quarterly pro-forma cash burn of NOK 5.9 million. Going forward, on top of this, one-off costs related to the divestment of the Nordic IaaS Platform are expected to continue into the second half of 2025.

FINANCIAL SITUATION

At 30.06.2025 Huddlestock reports a cash position of NOK 10.6 million, which is supported by 4,647,608 Done.ai Group AB shares received subsequent to the reporting period in connection with the Divestments. 20 percent of these shares will be distributed to Huddlestock’s shareholders, with more information to be disclosed in due course. The remaining 80 percent of the shares, with a current market value of NOK 40.9 million, will be used as a source of funding for Huddlestock’s expansion into continental Europe.

STRATEGY AND OUTLOOK

After the Huddlestock’s reshaping, the Company continues its operations with an asset light IaaS business model focused on the European market while developing its profitable consulting business, Visigon. Through its stake in Done.ai, the Company now holds a funding source for the expansion. With a strengthened organization, including the native German CFO Sabine Merky starting 1 October 2025, the Company will continue to pursue its vision of delivering innovative solutions that will shape the future of investing.

Visigon will be Huddlestock’s primary revenue source in the second half of 2025, with expectations of a strong second half of 2025 which is expected to bring the full year revenue in line with that of 2024. The Company has an ambition to sign a LOI with a second customer to the European IaaS Platform within 2025, and to turn the European IaaS Platform cash flow positive during 2026.

PRESENTATION AND Q&A

The Company's Chairman of the Board, Øyvind Hovland, and the CEO Leif Arnold Thomas, will host a webcast presentation of the results today  in English at 10:00 CEST, followed by a Q&A session.

During the presentation, Simon Lange, Managing Director of GIGA Broker GmbH and Co-CEO of AVL, will join as a guest speaker. He will provide insights into the German market and outline the key intentions and objectives behind the agreement between Huddlestock and GIGA Broker.

To participate, please register your interest with:

https://events.teams.microsoft.com/event/ac3c354a-53a1-4f5c-8646-a6236569977b@c1a5a59d-592c-49a2-ada8-beedc552d1f5

Disclosure regulation

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Contacts
  • Leif Arnold Thomas, Chief Executive Officer, Huddlestock Fintech AS, +47 982 15 520, leif.thomas@huddlestock.com
About Huddlestock Fintech AS

Huddlestock is an innovative technology software provider through its Investment-as-a-service offering, with full operational service support and a leading financial Consultancy services business. We deliver innovative and sustainable technology and operational solutions to companies offering financial products and services.

Find out more at huddlestock.com

Attachments
  • Download announcement as PDF.pdf
  • Huddlestock Fintech AS H1 2025 Report.pdf
  • Huddlestock Fintech AS - H1 2025 Presentation.pdf
English

Q-Interline A/S afsøger muligheder for at gennemføre en kapitaludvidelse

For at understøtte den fortsatte stærke vækst og sikre profitabel drift har bestyrelsen i Q-Interline besluttet at igangsætte en afsøgning af mulighederne for at styrke kapitalberedskabet indenfor de kommende 6 måneder

Selskabsmeddelelse nr. 37 Tølløse, den 28. august 2025. Meddelelsen indeholder intern viden.

Med udgangspunkt i Q-Interlines vedtægter §5.1, som omhandler bestyrelsens bemyndigelse til at forhøje selskabskapitalen, har bestyrelsen besluttet at afsøge mulighederne for at gennemføre en kapitalforhøjelse, enten ved at udstede nye aktier til favørkurs med fortegningsret til eksisterende aktionærer, eller ved at udstede nye aktier til markedskurs uden fortegningsret for de eksisterende aktionærer.

Vi befinder os i en fase, hvor vi har opnået en stærk geografisk dækning gennem en målrettet international ekspansion. Over de seneste år har vi etableret os på de vigtigste markeder med egne datterselskaber og en kompetent, lokal forankret organisation i Tyskland, Frankrig og USA samt Storbritannien. Parallelt hermed har vi udbygget og styrket vores netværk af distributører, hvilket har givet os en bred og solid markedsdækning.

Denne kommercielle platform har dannet grundlag for en betydelig vækst i vores tilbagevendende omsætning (ARR), drevet af salg af softwarelicenser, supportaftaler og forbrugsdele. Dette har skabt grundlaget for en robust forretningsmodel med høj grad af skalerbarhed og øget forudsigelighed.

Formålet med den potentielle kapitalforhøjelse er at sikre tilstrækkelig likviditet til at forebygge udsving i salget hen over året og dermed fastholde en stabil og sund drift. Kapitalen vil bidrage til at styrke vores finansielle beredskab i en fase, hvor fokus er rettet mod at konsolidere forretningen og skabe grundlag for langsigtet, profitabel vækst.

"Q-Interline er nu inde i en skaleringsfase, hvor vi har udsigt til at blive profitable inden for en overskuelig tidshorisont. Men det er essentielt, at kapitalberedskabet er på plads i denne overgangsperiode, indtil vi genererer tilstrækkelige likvide midler gennem den løbende drift. Det vil ruste os bedre til at imødekomme perioder med lavere salg af systemer og sikre, at vi kan fastholde momentum i vores udvikling,"udtaler CEO Martin Roithner Henriksen.

Q-Interline A/S, som er noteret på Nasdaq First North Growth Marked Copenhagen (QINTER), er forpligtet til at offentliggøre ovenstående information i henhold til compliance med EU’s Markedsmisbrugsforordning punkt 17.

Yderligere oplysninger:Q-Interline A/S:Stengårdsvej 7DK – 4340 TølløseCVR-nummer: 19614409Hjemmeside www.q-interline.com

Kontakter:

Martin Roithner HenriksenCEO / adm. DirektørTlf.: (+45) 53 80 06 09E-mail: mrh@q-interline.com

Certified AdviserNorden CEF A/SJohn NordenTlf.: (+45) 20 72 02 00jn@nordencef.dk

KommunikationGullev & Co. ApSBoris GullevTlf.: (+45) 31 39 79 99E-mail: borisgullev@gmail.comwww.gullev.co

Om Q-Interline A/S

Q-Interline er en ingeniørvirksomhed, som udvikler højteknologiske analyseløsninger til optimering af proces- og produktkvalitet, baseret på infrarød spektroskopi og korrekt prøveudtagning.

Q-Interline udvikler dels egne front-end software løsninger og dels software til automatisk cloud-overvågning af både analyseinstrumenter og matematiske kalibreringsmodeller.

Selskabet er blandt de førende leverandører af analyseudstyr til mejerisektoren i Skandinavien, og Q-Interline har leveret analysesystemer til kunder i 44 lande verden over inden for fødevare- og mejeriindustrien, landbrug, farmaceutisk og kemisk industri.

Selskabet har gennem mere end 28 år akkumuleret branchekendskab og udviklet nye innovative patenterede løsninger til fødevareanalyse, og står i dag med en konkurrencedygtig produktportefølje baseret på førende teknologi.

Q-Interline bidrager på den måde til bæredygtig anvendelse af klodens råvarer, der bruges til fødevareproduktion, og sikrer samtidigt, at kvaliteten af de producerede fødevarer fremmer menneskers og dyrs helbred og velbefindende.

 

Vedhæftninger
  • Download selskabsmeddelelse.pdf
Danish

Employment Fund's Supervisory Board Proposes an Increase in Unemployment Insurance Contributions

Stock Exchange Release       Employment Fund       August 28, 2025 at 13.05

Employment Fund’s Supervisory Board has approved the Fund's budget for 2026 and decided to propose to the Ministry of Social Affairs and Health an increase in the total aggregate amount of unemployment insurance contributions by 0.6 percentage points for 2026 at its meeting on Thursday, August 28, 2025. The decision is in accordance with the proposal of the Employment Fund’s Board of Directors.  

The employer's average unemployment insurance contribution would be 0.92 percent of salary, which is 0.3 percentage points more than in 2025. The employer's average contribution includes a separate 0.02 percentage point common contribution that is used to finance the transition security. The employee’s contribution would be 0.89 percent of salary, which is 0.3 percentage points more than in 2025.      

According to the proposal, the employer’s lower contribution would be 0.31 percent of the wage sum (up to a maximum of appr. EUR 2.5 million per year) and the higher contribution would be 1.23 percent of the wage sum (for the part that exceeds EUR 2.5 million).    

The employer's part-owner contribution would be 0.31 percent of the salary, which is 0.11 percentage points more than in 2025. The employee's part-owner contribution would be 0.39 percent of the salary, which is 0.12 percentage points more than in 2025.  

In addition, the Supervisory Board proposes that for the year 2026 the full transition security multiplier, that is used for determining the amount of transition security contribution, would be set to be 2.2, which is the same as in 2025.   

An employee whose earnings level would be 4,000 euros per month would pay unemployment insurance contributions of 427.20 euros per year (35.60 euros per month) in 2026, which is 144 euros more than in 2025.   

The proposition on unemployment insurance contributions is based on forecasts and calculations used by Employment Fund, which have also been used to draw up the Fund’s budget for 2026. These have taken into account different alternatives for the development of the economy and employment, as well as the effects of the Government programme’s entries and implemented legislative changes.   

According to the forecasts used by Employment Fund, the economic situation in Finland has weakened and will remain challenging in 2025, but the situation will improve in 2026. The forecast environment contains high uncertainty. Employment Fund's basic forecast predicts that the unemployment rate will be approximately 9.4% in 2025 and will decrease to 8.9% in 2026.    

The cost-reducing effect of the Government programme’s entries and legislative changes implemented by the Government on the expenses under Employment Fund’s financial responsibility is estimated to be around 700 million euros more in 2025 than in previous year and around 100 million euros more in 2026.    

According to the basic forecast prepared by Employment Fund, the change in the Fund's net assets will be approximately EUR 740 million negative in 2025 and would increase to approximately EUR 5 million positive in 2026 at the proposed payment level. With the proposed payment level, the Fund’s business cycle buffer would be clearly below the forecast maximum amount at the end of 2026.   

“The weak employment development has continued longer than expected, but in 2026 the economy and employment are predicted to pick up, although the unemployment level will still remain high. In 2024 and 2025, the level of unemployment insurance contributions has been reduced despite the challenging economic and employment situation by using the funds accumulated in the Employment Fund’s business cycle buffer. Despite the increase, the level of payments will remain low: compared to the level in 2023, the level in 2026 will be 1.2 percentage points lower”, says Employment Fund’s Managing Director Janne Metsämäki.   

“This year, the business cycle buffer is forecast to decrease further by over 700 million euros due to reduced revenues resulting from the reductions in unemployment insurance contributions and a higher-than-expected unemployment rate, despite the expenditure-reducing effect of the legislative changes implemented by the Government. The outlook for next year, especially regarding the level of unemployment, remains weak. The expenditure-reducing effects of legislative changes are not expected to increase significantly next year. In addition, we take into account the upcoming bond maturity in 2027. As a result of these factors, we estimate that there is a need to increase the unemployment insurance contributions", says Karo Nukarinen, Employment Fund’s Chief Financial Officer.  

The Finnish Parliament will confirm the final unemployment insurance contributions in autumn. The unemployment insurance contributions are specified by law every year.      

Employment Fund's Budget for 2026

Employment Fund’s Supervisory Board has approved the Fund’s budget for the year 2026.  

Figures are in millions of euros. 

Key Figures   

2025e*    

Budget 2026    

Change  (EUR millions)  

Unemployment insurance contributions and other income without state and municipal contributions  

1,227   

1,909 

681  

State and municipal contributions   

693   

645 

-49 

Financing contributions paid, administrative expenses and net financial income  

-2,664   

-2,548 

117 

Change in net position   

-744   

749   

Net position  

528  

533 

The maximum amount of the business cycle buffer  

1,279  

1,296 

17 

Change (percentage points)

Unemployment insurance contribution % (employers, average)  

0.62   

0.92 

0.3 

Unemployment insurance contribution % (employees) 

0.59   

0.89   

0.3 

Change in the total wage sum %   

2.5  

3.6 

1.1   

Unemployment rate % (average)  

9.4  

8.9 

-0.5 

* 2025 figures are unaudited estimates ​   Source: Employment Fund and Statistics Finland (unemployment rate)  

Helsinki, 28 August 2025  Employment Fund       Karo Nukarinen    Chief Financial Officer     

Further information:      Janne Metsämäki, Managing Director, +358 40 522 3614      Kari Nukarinen, Chief Financial Officer, +358 50 564 0920     

Distribution:  NASDAQ OMX Helsinki       Media       www.tyollisyysrahasto.fi       

About Työllisyysrahasto

The Employment Fund brings comfort in the changes of the working life. We collect the unemployment insurance contributions that are among other things financing the earnings-related unemployment benefits and urging forward the innovation of learning with the adult education allowance.

Attachments
  • Download announcement as PDF.pdf
English, Finnish

Sisäpiiritieto: Piippo Oyj on allekirjoittanut sitovan esisopimuksen Manillan Oy:n koko osakekannan myymisestä Inka Oy:lle

Piippo Oyj (”Myyjä” tai ”Piippo”) ja Inka Oy (”Ostaja” tai ”Inka”) ovat allekirjoittaneet tänään 28.8.2025 sitovan esisopimuksen (”esisopimus”), jossa Inka ostaa 100 % Manilla Oy:n (”Yhtiö” tai ”Manilla”) osakkeista (”Kauppa”).

Esisopimuksen tarkoituksena on sitovasti todeta Osapuolten tarkoitus toteuttaa Kauppa. Kaupan tavoiteltu allekirjoituspäivä (”Signing-päivä”) on 17.10.2025 ja Kaupan voimaantulo (”Closing-päivä”) viimeistään 31.10.2025. Esisopimuksessa sovittu alustava Manilla Oy:n osakkeiden nettovelaton kauppahinta on noin 0,6 miljoonaa euroa. Lopullinen Kauppahinta oikaistaan vahvistettujen tilinpäätösten 30.9.2024 ja 30.9.2025 perusteella. Kaupan toteutumisen edellytyksenä on Due Diligence -tarkastus, osapuolten sopiminen lopullisesta kauppakirjasta, Ostajan hallituksen hyväksyntä Kaupalle ja Kaupalle myönnetty rahoitus.

Inka on suomalainen perheyritys ja johtava teknisten kapeiden tekstiilinauhojen valmistaja pohjoismaissa. Yli 125 vuoden ikäinen yritys valmistaa Virtain Killinkoskella kudottuja ja punottuja nauhoja, nyörejä ja kuminauhoja, joita käytetään vaativilla toimialoilla, kuten puolustusteollisuudessa, tekstiiliteollisuudessa, logistiikassa ja ajoneuvoteollisuudessa. Inkalla työskentelee noin 40 osaavaa ammattilaista. Vuonna 2019 perustettu Manilla Oy maahantuo ja välittää sitomiseen, kiinnittämiseen ja nostamiseen liittyviä kuluttajatuotteita Suomessa ja lähialueilla. Manilla Oy työllistää kolme (3) henkilöä ja ostaa tarvitsemansa varastointi-, hallinto- ja toimitilapalvelut Piipolta.

Piipon päätös myydä tytäryhtiö Manillan koko osakekanta on osa aiemmin aloitettua strategiatyötä. Piippo on aiemmin tiedottanut jatkavansa selvitystyötä Piipon emoyhtiön, ja Manilla Oy:n tulevaisuudesta ja tiedottanut arvioivansa mahdollisuutta jatkaa liiketoimintaa sekä muun muassa mahdollisuutta myydä jäljellä oleva liiketoiminta tai toteuttaa niin sanottu käänteinen listautuminen listautumista suunnittelevan yhtiön kanssa. Lisäksi Piippo tiedottanut selvittävänsä mahdollisuuksia myydä omistamansa kiinteistöt Outokummussa ja Lempäälässä.

PIIPPO OYJ

Yhteyshenkilöt
  • Mikko Anttila, Toimitusjohtaja, Piippo Oyj, +358 50 521 4011, mikko.anttila@piippo.fi
  • Sisu Partners Oy, Juha Karttunen, Hyväksytty neuvonantaja, +358 40 555 4727
Tietoja julkaisijasta Piippo Oyj

Piippo Oyj:n ydinliiketoimintaa ovat paalausverkot ja -langat. Olemme kansainvälisesti alan yksi johtavista toimijoista. Yhtiön globaali jakeluverkosto kattaa jo yli 40 maata. Piippo Oyj:n osakkeet on listattu Nasdaq Helsinki Oy:n ylläpitämällä First North Growth Market Finland -markkinapaikalla.

Liitteet
  • Lataa tiedote pdf-muodossa.pdf
Finnish

Dataproces Group A/S presents Quarterly Financial Report – Q1 2025/26

Company announcement no. 16/2025: Dataproces Group A/S presents Quarterly Financial Report for Q1 2025/26

Dataproces' revenue increased by 17% compared to the same period last year, and ARR on continuing products has increased to DKK 24.6 million in the first quarter of the financial year 

Dataproces' CEO Michael Binderup states:

With the report for the first quarter of 2025/26, Dataproces shows stable and continued growth.

The quarter's results are close to the strong financial statements for 2024/25 with continued high customer activity and sales to both existing and new customers. 

We have succeeded in retaining all Danish and German customers from the Boelplan acquisition in the spring and are working hard to ensure that our access to the German market will yield more agreements in the coming time. 

After a few years with full focus on tight cost management, Dataproces is now in a situation where liquidity is so strong that we can invest in both product development and new markets. 

On the product side, there are several news items on the way that we have high expectations for. 

The financial balance of the company is healthy and Dataproces is in a strong position with a focus on continued growth through new products, new markets and possible acquisitions. 

We are very satisfied with the development that Dataproces is experiencing, and we maintain our expectations for the year, as guided in company announcement no. 5/2025. 

Dataproces expectations for 2025/26

    • ARR growth of 20-35% compared to 2024/25
    • Revenue of DKK 44 - 50 million.  
    • EBITDA of DKK 16 - 20 million. 
    • EBIT of DKK 7 - 10 million.   

Financial key figures for the period 1 May 2025 – 31 July 2025 

 DKK THOUSAND

Q1          2025/26 (3 months)

Q1         2024/25 (3 months)

 

      2024/25 (12 months)

Revenue

9.625

8.215

 

44.436

- Revenue Software

4.301

4.480

 

23.780

- Revenue Data analyses og Others

5.324

3.735

 

20.656

Gross profit

9.421

8.409

 

43.175

Earnings before depreciations (EBITDA)

2.435

2.897

 

17.930

Nett Financial expenses

32

-219

 

-218

Profit for the year

476

648

 

6.446

Equity

28.340

21.431

 

27.219

Total Equity and Liabilities/Total assets

47.805

39.163

 

55.415

Cashflow from operating activities

-2.669

-1.298

 

19.652

Cashflow from investment activities

-2.067

-1.761

 

-9.187

- Investment in tangible assets

-29

-53

 

-461

Cashflow from financing activities

586

51

-110

 

 

 

 

 

Key Figures

 

 

 

 

# Software contracts (SaaS)

173

153

 

171

Annual Recurring Revenue (ARR)

24.639

17.844

 

23.807

Solvency (equity/totalt assets)

60%

55%

 

49%

Statements about the future

This report contains statements about the future - including statements about Dataproces Group A/S' future operating results, financial position, cash flows, business strategy and future objectives. The statements are based on expectations or predictions that management deems reasonable at the time of publication of this report. Statements about the future are associated with risks and uncertainty as well as a number of factors, many of which will be beyond control of the company. This may mean that the actual development and the actual result deviate significantly from the expectations in the report. Without being exhaustive, such factors include general economic and business conditions, including market, competition and supplier conditions, as well as financial and regulatory conditions.

Contacts
  • John Norden, Certified Advisor, JN@nordencef.dk
  • Michael Binderup, CEO, +45 41 91 20 07, mib@dataproces.dk
About Dataproces Group A/S

Dataproces is an innovative Software and consulting house, specializing in AI-supported solutions targeted at the Danish municipalities and their digital administration. The solutions range widely from robot technology and SaaS to data analyzes as well as collaboration and consulting. The starting point and purpose are always the same: to use data to create new knowledge, smarter processes and increased efficiency for the benefit of both citizens and municipalities.

Dataproces – we create value with data!

Attachments
  • Download announcement as PDF.pdf
  • Dataproces Group Kvartalsrapport Q1 2025-26.pdf
Danish, English

Asuntosalkku Oyj aloittaa uuden omien osakkeiden osto-ohjelman yhtiön pääomarakenteen kehittämiseksi

Asuntosalkku Oyj – Muut pörssin sääntöjen nojalla julkistettavat tiedot – 28.8.2025 klo 10.40

Asuntosalkku Oyj aloittaa uuden omien osakkeiden osto-ohjelman yhtiön pääomarakenteen kehittämiseksi

Asuntosalkku Oyj:n hallitus päätti varsinaisen yhtiökokouksen 23.1.2025 antaman valtuutuksen perusteella uudesta yhtiön omien osakkeiden osto-ohjelmasta.

Osto-ohjelmassa hankittavien osakkeiden enimmäismäärä on 8 000, joka vastaa noin 0,8 prosenttia yhtiön osakkeista. Osakkeiden hankintaan käytetään kuitenkin enintään 700 000 euroa.

Osakkeet hankitaan muuten kuin osakkeenomistajien omistusten mukaisessa suhteessa Nasdaq Helsinki Oy:n ylläpitämällä Nasdaq First North Growth Market Finland -markkinapaikalla järjestetyssä julkisessa kaupankäynnissä hankintahetken markkinahintaan. Omien osakkeiden hankinta aloitetaan aikaisintaan 1.9.2025 ja lopetetaan viimeistään 12.12.2025. Omien osakkeiden hankinta rahoitetaan yhtiön jakokelpoisella vapaalla omalla pääomalla.

Yhtiön omien osakkeiden hankinnan tarkoituksena on yhtiön pääomarakenteen kehittäminen ja osinkopolitiikan toteuttaminen.

Asuntosalkku Oyj:llä on yhteensä 986 592 osaketta. Nykyinen osto-ohjelma on voimassa vielä 29.8.2025 asti. Asuntosalkku Oyj:n omistuksessa oli yhteensä 11 913 omaa osaketta edellisen kauppapäivän päättyessä 27.8.2025.

 

Lisätietoja

Asuntosalkku Oyj

Jaakko SinnemaatoimitusjohtajaPuh. +358 41 528 0329

jaakko.sinnemaa@asuntosalkku.fi

 

Hyväksytty neuvonantajaAktia Alexander Corporate Finance Oy

Puh. +358 50 520 4098

 

Asuntosalkku Oyj

Asuntosalkku on vaihtoehto asuntorahastoille ja suoralle asuntosijoittamiselle. Se on Viron suurin markkinaehtoinen vuokranantaja ja Tallinnan vuokramarkkinoiden edelläkävijä. Asuntosalkku on asuntosijoitusyhtiö, joka keskittyy omistaja-arvon luomiseen. Sijoitukset painottuvat omistusasuntotaloista valikoituihin yksittäisiin asuntoihin, joissa vuokralainen asuu omistusasujien naapurina. Pääpaino on hyvien sijaintien pienissä asunnoissa Suomen pääkaupunkiseudulla ja sen kehyskunnissa sekä Tallinnan keskusta-alueilla.

31.3.2025 Asuntosalkku omisti Suomessa 1 413 valmista asuntoa, joiden yhteenlaskettu käypä arvo velattomana oli 160,1 miljoonaa euroa, sekä Tallinnassa 676 valmista asuntoa, joiden yhteenlaskettu käypä arvo oli 104,2 miljoonaa euroa. Asuntosalkun taloudellinen vuokrausaste 30.6.2025 oli 97,3 prosenttia.

Asuntosalkun perustajat ovat Jaakko Sinnemaa ja Timo Metsola. He ovat yhtiöidensä kautta myös Asuntosalkun keskeisiä omistajia.

www.asuntosalkku.fi

Liitteet
  • Lataa tiedote pdf-muodossa.pdf
Finnish

RTX initiates a 20 DKKm share buy-back program

Nørresundby, 28 August 2025Company Announcement no 16/2025

The Board of Directors of RTX A/S has decided to initiate a new share buy-back program of up to DKK 20 million to be executed during the period 1 September 2025 to 1 September 2026.

The share buy-back program is initiated pursuant to the authorization granted to the Board of Directors by the Annual General Meeting on 25 January 2024, which authorizes RTX to acquire treasury shares at a nominal value not exceeding 10% of the share capital.

The share buy-back is executed in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor Regulation. RTX is entitled to suspend or stop the program at any time subject to announcement to Nasdaq Copenhagen. Any such decision will be disclosed to the public in a company announcement.

The guiding principle for the policy on capital allocation and structure of RTX is to: (i) maintain sufficient financial flexibility to realize RTX’s strategic objectives, including investments into growth opportunities as well as balance sheet robustness needed for long term framework agreements, which are needed to support operations. At the same time (ii) ensuring a financial structure maximizing the return for our shareholders.

RTX has appointed Danske Bank as lead manager for the share buy-back program. Danske Bank will make its own trading decisions and act independently of and without influence or involvement from RTX as required by the Safe Harbor Regulation.

Under this share buy-back program RTX may repurchase shares up to a maximum amount of DKK 20 million, and no more than 846,783 shares, corresponding to 10% of the share capital of RTX A/S.

Shares acquired under the program cannot be purchased at a price exceeding the higher of (i) the price of the latest independent transaction on Nasdaq Copenhagen and (ii) the price of the highest independent bid on Nasdaq Copenhagen at the time of the transaction.

The total number of shares that may be purchased on a single trading day may not exceed 25% of the average daily trading volume over the preceding 20 trading days on Nasdaq Copenhagen.

As of 28 August 2025, RTX holds 489,362 treasury shares of a nominal value of DKK 5, equal to 5.78% of the share capital.

Upon initiation of the program, RTX will issue a weekly announcement in respect of transactions made under the program.

 

Enquiries and further information:

CEO Henrik Mørck Mogensen, tel +45 96 32 23 00

CFO Mille Tram Lux, tel +45 96 32 23 00

Contacts
  • Henrik Mørck Mogensen, CEO, RTX A/S, +45 96322300, hmm@rtx.dk
  • Mille Tram Lux, CFO, +45 96322300, mtl@rtx.dk
About RTX

RTX innovates, designs, and manufactures wireless communication solutions within Enterprise, Healthcare, and ProAudio. Working in close partnership with our customers, we offer customized, 'turn-key', end-to-end solutions with full product lifecycle management designed to make a difference in the market. We are a global company employing 300+ people at our locations in Denmark, Hong Kong, Romania and USA.

Attachments
  • Download announcement as PDF.pdf
  • RTX CA No 16-2025 - 28.08.25 - New share buy-back programme.pdf
Danish, English